Can Fite (Israel) Financial Diagnostics

CANF -- Israel Stock  

ILS 112.10  4.70  4.38%

The big decline in price over the last few months for Can Fite BioPharma could raise concerns from investors as the firm closed today at a share price of 109.5 on 121983.000 in volume. The company executives failed to add value to investors and positioning the firm components to exploit market volatility in March. However, diversifying your holdings with Can Fite BioPharma Ltd or any similar stocks can still protect your portfolios during high-volatility market scenarios. The stock standard deviation of daily returns for 30 days (very short) investing horizon is currently 9.1294. The very high volatility is mostly attributed to the latest market swings and not very good earning reports from some ot the Can Fite partners. This diagnostics interface makes it easy to digest most current publicly released information about Can Fite as well as get updates on important government artifacts including earning estimates, SEC corporate filings and announcements. This module also helps to analysis Can Fite price relationship with some important fundamental indicators such as market cap and management efficiency. Check also Trending Equities.

Can Fite Note

The company recorded loss per share of 0.17. Can Fite BioPharma had not issued any dividends in recent years. The entity had a split on 2013-05-12. Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of autoimmune-inflammatory, oncological, and liver diseases. The company was founded in 1994 and is headquartered in Petah-Tikva, Israel. Can Fite operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange. It employs 7 people. For more info on CAN-FITE BIOPHARMA please contact Pnina Fishman at 972 3 924 1114 or go to

Can Fite BioPharma Alerts

Can Fite BioPharma is not yet fully synchronised with the market data
Can Fite BioPharma generates negative expected return over the last 30 days
Can Fite BioPharma has high historical volatility and very poor performance
The company reported revenue of 3.82M. Net Loss for the year was (6.57M) with profit before overhead, payroll, taxes, and interest of 3.82M.
CAN-FITE BIOPHARMA has accumulated about 3.89M in cash with (4.16M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.09.

Market Capitalization

The company currently falls under 'Micro-Cap' category with current market capitalization of 62.38M.


The company has Profit Margin (PM) of (172.02) % which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (141.73) % which suggests for every $100 dollars of sales it generated a net operating loss of -1.42.

Management Efficiency

Can Fite BioPharma has return on total asset (ROA) of (43.48) % which means that it has lost $43.48 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of (163.68) % meaning that it generated substantial loss on money invested by shareholders.

Can Fite Technical and Predictive Indicators

Did you try this?

Run Portfolio Rebalancing Now


Portfolio Rebalancing

Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
All  Next Launch Module
Check also Trending Equities. Please also try Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.